The impact of cannabis use proximal to sleep and cannabinoid metabolites on sleep architecture
- PMID: 38804689
- PMCID: PMC11446118
- DOI: 10.5664/jcsm.11212
The impact of cannabis use proximal to sleep and cannabinoid metabolites on sleep architecture
Abstract
Study objectives: Cannabis is a common sleep aid; however, the effects of its use prior to sleep are poorly understood. This study aims to determine the impact of nonmedical whole plant cannabis use 3 hours prior to sleep and measured cannabis metabolites on polysomnogram measures.
Methods: This is a cross-sectional study of 177 healthy adults who provided detailed cannabis use history, underwent a 1-night home sleep test and had measurement of 11 plasma and urinary cannabinoids, quantified using mass spectroscopy, the morning after the home sleep test. Multivariable models were used to assess the relationship between cannabis use proximal to sleep, which was defined as use 3 hours before sleep, and individual home sleep test measurements. Correlation between metabolite concentrations and polysomnogram measures were assessed.
Results: In adjusted models, cannabis use proximal to sleep was associated with increased wake after sleep onset (median 60.5 vs 45.8 minutes), rate ratio 1.59 (1.22, 2.05), and increased proportion of stage 1 sleep (median 15.2% vs 12.3%), effect estimate 0.16 (0.06, 0.25). Compared to nonusers, frequent cannabis users (> 20 days per month) also had increased wake after sleep onset and stage 1 sleep, in addition to increased rapid eye movement latency and decreased percent sleep efficiency. Δ9-tetrahydrocannabinol metabolites correlated with these home sleep test measures.
Conclusions: Cannabis use proximal to sleep was associated with minimal changes in sleep architecture. Its use was not associated with measures of improved sleep including increased sleep time or efficiency and may be associated with poor quality sleep through increased wake onset and stage 1 sleep.
Citation: Althoff MD, Kinney GL, Aloia MS, Sempio C, Klawitter J, Bowler RP. The impact of cannabis use proximal to sleep and cannabinoid metabolites on sleep architecture. J Clin Sleep Med. 2024;20(10):1615-1625.
Keywords: cannabinoid; cannabis; metabolite; polysomnography; sleep.
© 2024 American Academy of Sleep Medicine.
Conflict of interest statement
All authors have seen and approved the manuscript. Institution where work was performed: National Jewish Health and University of Colorado Anschutz Medical Campus. This work was supported by grant funding from the Colorado Department of Public Health & Environment, Denver, Colorado starting in 2015. Grant title “Colorado Cannabis Cohort: Efficacy, Safety, and Usage Patterns of Medical Marijuana for Sleep.” M.D.A. is supported by the National Institutes of Health/National Center for Advancing Translational Sciences Colorado Clinical and Translational Science Awards Grant Number K12 TR004412. Dr. Aloia reports holding stock in Philips. The other authors report no conflicts of interest.
Similar articles
-
Pharmacotherapies for sleep disturbances in dementia.Cochrane Database Syst Rev. 2016 Nov 16;11(11):CD009178. doi: 10.1002/14651858.CD009178.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Nov 15;11:CD009178. doi: 10.1002/14651858.CD009178.pub4. PMID: 27851868 Free PMC article. Updated.
-
Non-pharmacological interventions for sleep promotion in hospitalized children.Cochrane Database Syst Rev. 2022 Jun 15;6(6):CD012908. doi: 10.1002/14651858.CD012908.pub2. Cochrane Database Syst Rev. 2022. PMID: 35703367 Free PMC article.
-
Melatonin for the promotion of sleep in adults in the intensive care unit.Cochrane Database Syst Rev. 2018 May 10;5(5):CD012455. doi: 10.1002/14651858.CD012455.pub2. Cochrane Database Syst Rev. 2018. PMID: 29746721 Free PMC article.
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
Cannabinoid content on product labels influences cannabis health perceptions.Ann Behav Med. 2025 Jan 4;59(1):kaaf046. doi: 10.1093/abm/kaaf046. Ann Behav Med. 2025. PMID: 40553093
References
-
- Adjaye-Gbewonyo D , Ng AE , Black LI . Sleep difficulties in adults: United States, 2020 . NCHS Data Brief. 2022. ;( 436 ): 1 – 8 . - PubMed
-
- Reuben C , Elgaddal N , Black LI . Sleep medication use in adults aged 18 and over: United States, 2020 . NCHS Data Brief. 2023. ;( 462 ): 1 – 8 . - PubMed
-
- Substance Abuse and Mental Health Services Administration . Key substance use and mental health indicators in the United States: results from the 2021 National Survey on Drug Use and Health. (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; ; 2022. .
-
- Bonn-Miller MO , Boden MT , Bucossi MM , Babson KA . Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users . Am J Drug Alcohol Abuse. 2014. ; 40 ( 1 ): 23 – 30 . - PubMed
-
- Earl DC , Proano M . Updates in the use of cannabis for insomnia . Curr Opin Pulm Med. 2022. ; 28 ( 6 ): 511 – 514 . - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources